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Abstract
Asenapine is a new antipsychotic drug that induces a long-lasting behavioral sensitization in adult
rats. The present study investigated the developmental impacts of adolescent asenapine treatment
on drug sensitivity and on 3 proteins implicated in the action of antipsychotic drugs (i.e. Brain-
derived neurotrophic factor (BDNF), dopamine D2 receptor, and ΔFosB) in adulthood. Male
adolescent Sprague-Dawley rats (postnatal days, P 43-48) were first treated with asenapine (0.05,
0.10 or 0.20 mg/kg, sc) and tested in the conditioned avoidance or PCP (2.0 mg/kg, sc)-induced
hyperlocomotion tasks for 5 days. After they became adults (∼P 76), asenapine sensitization was
assessed in a single avoidance or PCP-induced hyperlocomotion challenge test with all rats being
injected with asenapine (0.10 mg/kg, sc). Rats were then sacrificed 1 day later and BDNF, D2 and
ΔFosB in the prefrontal cortex, striatum and hippocampus were examined using Western blotting.
In adolescence, repeated asenapine treatment produced a persistent and dose-dependent inhibition
of avoidance response, spontaneous motor activity and PCP-induced hyperlocomotion. In the
asenapine challenge test, adult rats treated with asenapine (0.10 and 0.20 mg/kg) in adolescence
made significantly fewer avoidance responses and showed a stronger inhibition of spontaneous
motor activity than those previously treated with saline. However, no group difference in the
levels of BDNF, D2 and ΔFosB expression was found. These findings suggest that although
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adolescent asenapine treatment for a short period of time induces a robust behavioral sensitization
that persists into adulthood, such a long-term effect is not likely to be mediated by BDNF, D2 and
ΔFosB.
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Asenapine; Conditioned avoidance response; Phencyclidine; Locomotor activity; Adolescence;
Sensitization; BDNF; Dopamine D2 receptor; ΔFosB; Ultrasonic vocalization
1 Introduction
Antipsychotic treatment in children and adolescents has increased dramatically in recent
decades. Epidemiological surveys conducted in many countries (e.g. UK, US, Germany,
Netherlands) indicate a 2- to 6-fold increase in the number of prescribed antipsychotic drugs
for young patients (≤ 20 years) between the 1990s and the mid-2000s [1-3]. As adolescence
is a unique period when the brain undergoes dramatic reorganization and frontal maturation,
it is conceivable that antipsychotic exposure during this period will alter brain development
and behavioral function in the long run. Recent preclinical studies suggest that this is indeed
the case. For example, periadolescent exposure to antipsychotic drugs such as olanzapine,
risperidone and clozapine is found to alter various neuroreceptors, including dopamine D1,
D2 and D4 receptors [4, 5], serotonin 5-HT1A and 5-HT2A receptors [6], and ionotropic
NMDA and AMPA glutamatergic receptors [7]. Adolescent antipsychotic treatment is also
shown to enhance rodents' sensitivity to amphetamine [5], impair their working memory in a
delayed non-match to sample test, delay the extinction process of shock-induced fear
memory in adulthood [8], and prevent the development of various psychosis-like behaviors
[9-12].
Our research on the long-term effects of antipsychotic treatment on behavioral and brain
functions throughout development has focused on the drug-induced alterations in drug
sensitivity from adolescence to adulthood [13-16]. As is often the case, repeated
administration of a psychotropic drug results in either an increase or decrease of a particular
behavioral effect of the drug, termed sensitization and tolerance, respectively [17]. Our
previous antipsychotic work on adult rats (> 70 days old) identify two similar behavioral
phenomena, which are termed antipsychotic sensitization and tolerance [18-23]. Using two
distinct behavioral tests of antipsychotic activity: conditioned avoidance response (CAR)
and PCP-induced hyperlocomotion, we showed that repeated administration of haloperidol,
olanzapine, asenapine or risperidone daily for 5-7 days in adult rats progressively increases
the drug's efficacy to inhibit avoidance responding and PCP-induced hyperlocomotion over
time (a within-subjects index of sensitization). A few days later, when all rats are given a
challenge dose of these drugs, they often make significantly fewer avoidance responses and
exhibit lower PCP-induced hyperlocomotion than those that are treated with these drugs for
the first time (a between-subjects index of sensitization). In contrast, repeated administration
of clozapine causes a decrease in its behavioral efficacy in these tests, indicating a tolerance
effect. In addition, our previous studies also indicate that antipsychotic sensitization that can
last up to 50 days [19], and are likely mediated by dopamine D2 and 5-HT2A receptor-
related neural plasticity [23].
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Recently we expanded our antipsychotic sensitization and tolerance work into the adolescent
period. We have demonstrated that adolescent antipsychotic treatment could induce
behavioral sensitization and tolerance that maintain into adulthood. Adolescent treatment of
olanzapine or risperidone causes a sensitization effect, whereas clozapine treatment in
adolescence causes a tolerance in adulthood [13-15, 24]. Rats treated with only 5 days of
olanzapine or risperidone in adolescence showed a stronger inhibition of CAR and PCP-
induced motor activity than those treated with vehicle when all rats were challenged with the
same antipsychotic drug in adulthood, whereas those treated with clozapine for 5 days in
adolescence showed a weaker inhibition than the vehicle rats. In addition, adolescent
risperidone treatment even altered adulthood responsiveness to other atypical drugs (e.g.
olanzapine and clozapine) [15]. Collectively, these findings provide strong evidence that
antipsychotic treatment in adolescence can induce a long-term change in drug
responsiveness that persists into adulthood.
The primary goal of the present study was to determine the generality of this observation by
examining whether asenapine, a newer atypical antipsychotic drug with a distinctive
receptor binding profile from other atypical antipsychotic drugs [25, 26], would also cause a
sensitization effect that persists from adolescence into adulthood. In addition, we attempted
to identify the possible molecular mechanisms underlying such a long-term behavioral
effect. Given that adolescent antipsychotic treatment is known to increase dopamine D2
receptors in certain forebrain regions [4, 5], and repeated antipsychotic treatment is shown to
induce a robust long-term change in BDNF and ΔFosB (a transcription factor), two
important biomarkers involved in brain plasticity and the action of chronic antipsychotic
treatment [27-31], we focused our attention on the D2, BDNF and ΔFosB levels in the
prefrontal cortex (PFC), striatum, and hippocampus in adult rats that had received either
asenapine or vehicle treatment in adolescence. These brain areas have been implicated in
antipsychotic action and the neuropathology of schizophrenia [32]). Our hypothesis was that
adolescent asenapine treatment would induce a sensitization effect that persists into
adulthood. In addition, we expected that adolescent asenapine treatment would also cause
long-lasting changes in the expression of D2, BDNF and ΔFosB levels parallel to the
behavioral sensitization.
2. Materials and methods
2.1. Animals
Adolescent male Sprague–Dawley rats from Charles River (Portage, MI; postnatal days, P
25-27 or P 35-37 upon arrival, averaged age were assumed to be ∼P 26 or ∼P 36) were
used. They were housed two per cage, in 48.3 cm × 26.7 cm × 20.3 cm transparent
polycarbonate cages under 12-h light/dark conditions (light on between 6:30 am and 6:30
pm). Room temperature was maintained at 22 ± 1°C with a relative humidity of 45-60%.
Food and water was available ad libitum. Rats were allowed at least 5 days of habituation to
the animal facility before being used in experiments (∼P 31 or ∼P 41). All behavioral tests
took place between 9 am and 5 pm in the light cycle. The experimental procedures were
approved by the Institutional Animal Care and Use Committee at the University of
Nebraska-Lincoln.
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2.2. Drugs and choice of doses
Asenapine Maleate (ASE, a gift from the NIMH drug supply program) was dissolved in
0.9% saline. Doses of asenapine (0.05, 0.10 and 0.20 mg/kg) were determined on the basis
of our literature review showing that this dose range of asenapine causes a dose-dependent
suppression of CAR but does not cause severe motor impairment [33, 34]. These doses were
also chosen on the basis of our recent studies showing that asenapine at these doses induces
a dose-dependent and long-lasting sensitization in adult rats in the CAR test [18, 19].
Phencyclidine hydrochloride (PCP, gift from the NIDA Chemical Synthesis and Drug
Supply Program) was dissolved in 0.9% saline and tested at 2.00 mg/kg. All drugs were
administrated subcutaneously (sc) at 1.00 ml/kg.
2.3. Two-way avoidance conditioning apparatus and ultrasonic vocalization (USV)
apparatus
Eight identical two-way shuttle boxes custom designed and manufactured by Med
Associates (St. Albans, VT) were used. Each box was housed in a ventilated, sound-
insulated isolation cubicle (96.52 cm W × 35.56 cm D × 63.5 cm H). Each box was 64 cm
long, 30 cm high (from grid floor), and 24 cm wide, and was divided into two equal-sized
compartments by a partition with an arch style doorway (15 cm high × 9 cm wide at base). A
barrier (4 cm high) was placed between the two compartments, so the rats had to jump from
one compartment to the other. The grid floor consisted of 40 stainless-steel rods with a
diameter of 0.48 cm, spaced 1.6 cm apart center to center, through which a scrambled
footshock (unconditioned stimulus, US, 0.8mA, maximum duration: 5 s) was delivered by a
constant current shock generator (Model ENV-410B) and scrambler (Model ENV-412). The
rat location and crossings between compartments were monitored by a set of 16 photobeams
(ENV-256-8P) affixed at the bottom of the box (3.5 cm above the grid floor). Illumination
was provided by two houselights mounted at the top of each compartment. The conditioned
stimulus (CS, 76 dB white noise) was produced by a speaker (ENV 224 AMX) mounted on
the ceiling of the cubicle, centered above the shuttle box. Background noise (approximately
74 dB) was provided by a ventilation fan affixed at the top corner of each isolation cubicle.
All training and testing procedures were controlled by Med Associates programs running on
a computer.
In each CAR box, a USV microphone (P48 Avisoft Bioacoustics/Emkay Microphone,
Avisoft Bioacoustics, Berlin, Germany) was mounted on the ceiling of the two-compartment
chamber. The microphone was connected via an E-MU 0404 USB Audio device to a
computer. Acoustic data were displayed in real time by the Avisoft RECORDER, a multi-
channel triggering hard-disk recording software (version 3.4; Avisoft Bioacoustics), and
were recorded at a sampling rate of 192 kHz in 16 bit format and analyzed by Avisoft
SASLab Pro (version 4.51; Avisoft Bioacoustics).
2.4. Locomotor activity monitoring apparatus
Sixteen activity boxes were housed in a quiet room. The boxes were 48.3 cm × 26.7 cm ×
20.3 cm transparent polycarbonate cages, which were similar to the home cages but were
each equipped with a row of 6 photocell beams (7.8 cm between two adjacent photobeams)
placed 3.2 cm above the floor of the cage. A computer with recording software (Aero
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Apparatus Sixbeam Locomotor System v1.4, Toronto, Canada) was used to detect the
disruption of the photocell beams and recorded the number of beam breaks. All experiments
were run during the light cycle.
2.5. Experiment 1: Asenapine sensitization and associated D2 and BDNF protein
expression in asenapine-treated rats in the conditioned avoidance response test
This experiment examined whether the sensitization effect induced by asenapine in
adolescence could be maintained into adulthood and explored its potential molecular basis in
the CAR test. Table 1 details the experimental procedure, which involved avoidance
training, repeated asenapine testing, asenapine challenge test and D2 and BDNF Western
blotting.
Avoidance training in adolescence from P 33 to P 42—Forty rats (∼P 31) were
first habituated to the CAR boxes for 2 days (30 min/day) and then trained to make
avoidance responding for 10 consecutive days/sessions. Each daily session consisted of 30
trials. Every trial started by presenting a white noise (CS) for 10 s, followed by a continuous
scrambled foot shock (0.8 mA at maximum duration of 5 s) on the grid floor. If a subject
moved from one compartment into the other during the CS, it avoided the shock and this
shuttling response was recorded as avoidance. If the rat made a crossing upon receiving the
footshock, this response was considered as escape. If the rat did not respond during the
entire 5 s presentation of the shock, the trial was terminated and the next trial started after an
intertrial interval lapsed (randomly varied between 30 s to 60 s).
Five days of repeated asenapine testing in adolescence from P 43 to P 47—At
the end of the training session (∼P 42), rats were first matched based on the number of
avoidance response on the last training day (i.e. pre-drug) to create blocks of rats (n = 4 rats/
block). Within each block, they were then randomly assigned to 1 of 4 groups: ASE 0.05
mg/kg (ASE 0.05, n = 10), ASE 0.10 mg/kg (ASE 0.10, n = 10), ASE 0.20 mg/kg (ASE
0.20, n = 10) and saline (VEH, n = 10), and tested daily under the CS-only (30 trials/session,
no shock) condition for 5 consecutive days. During each drug test, rats were first injected
with asenapine or saline, 30 min later, they were placed in the CAR boxes and tested.
Ultrasonic vocalizations at the 22 kHz range (20-32 kHz) as a validated measure of
anxiolytic effect [35] were also recorded for the first 10 min of testing using Avisoft
Recorder software (Version 3.4). Settings included sampling rate at 192 kHz, format 16 bit.
For acoustical analysis, recordings were transferred to Avisoft SASLab Pro (Version 4.51)
and a fast Fourier transformation (FFT) was conducted. Spectrograms were generated with
an FFT-length of 256 points and a time window overlap of 50% (100% Frame, FlatTop
window). The spectrogram was produced at a frequency resolution of 750 Hz and a time
resolution of 0.6667 ms. Call detection was provided by an automatic single threshold-based
algorithm (threshold: −20 dB) and a hold-time mechanism (hold time: 0.02 s).
Avoidance retraining and asenapine challenge test on ∼P 76—Rats remained in
their home cages until ∼P 68 when all rats were returned to the CAR boxes for 1 habituation
session, followed by 7 days of CAR training/retraining under the CS-US condition (30 trials,
shock) to ensure all groups had a comparable level of avoidance responding before the
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sensitization assessment which was conducted 1 day after the 7th training session (∼P 76)
with all rats being injected with asenapine 0.10 mg/kg and tested under the CS-only
condition (30 trials, no shock) 30 min later. Numbers of avoidance response and 22 kHz
USV were recorded.
Western blot analysis—One day after the challenge test (∼P 77), 8 rats randomly
selected from each group were sacrificed by live decapitation and their brains were quickly
removed. The prefrontal cortex (PFC), striatum and hippocampus were dissected out over
ice according to the brain atlas [36], and were frozen on dry ice and stored at -80°C until
further analysis.
Tissues from these areas were first homogenized in ice-cold RIPA buffer, containing 25 mM
Tris/HCl (pH 7.6), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS (Thermo
Scientific, Rockford, IL) with Protease Inhibitor Cocktail (Thermo Scientific, Rockford, IL).
After centrifugation at 16,000g for 15 min, the supernatant was collected and protein
concentration was determined using the BCA Protein Assay Kit (Pierce, Rockford, IL).
Western blots were performed in duplicate with equal amount of proteins (40-50 μg/lane)
using the sodium dodecyl sulfate (SDS)-12% polyacrilamide gel (Bio-Rad, Hercules, CA).
Proteins were separated by electrophoresis at 80-120 V for 90 min (BDNF, D2 receptor and
β-actin), then electrophoretically transferred onto Polyvinylidene fluoride (PVDF)
membranes (Millipore, Billerica, MA) for 60 min at 300 mA in Tris/glycine buffer in a tank
transfer system (Bio-Rad, Hercules, CA). The PVDF membranes were blocked with 5%
nonfat dry milk in Tris-buffered saline (TBS) for 2 h at room temperature, and then
incubated with primary antibodies overnight at 4°C. Immunostaining was carried out using
the following antibodies: BDNF (1:100, Santa Cruz Biotechnology, Santa Cruz, CA), D2
(1:1000, EMD Millipore Corporation, Billerica, MA) and β-actin (1:800, Santa Cruz
Biotechnology, Santa Cruz, CA or 1:2000, Sigma-Aldrich, St. Louis, MO). After being
washed 3 times in TBS with 0.1% Tween 20 (TBST) at a 10-min interval, the membranes
were incubated with Odyssey anti-rabbit, anti-goat or anti-mouse secondary antibodies (Li-
COR Biosciences, Lincoln, NE), respectively, with 1:3000-1:5000 dilutions in TBST at
room temperature. One hour later, the membranes were washed 3 times at a 10-min interval
and the bands were visualized and quantified using Odyssey Fc Imager (Li-COR
Biosciences, Lincoln, NE) according to the manufacturer's instructions.
2.6. Experiment 2: Asenapine sensitization and associated ΔFosB protein expression in
asenapine-treated rats in the PCP-induced hyperlocomotion test
No prior study has demonstrated asenapine sensitization in this test of antipsychotic activity
in adolescent rats. In this experiment, we first validated whether asenapine sensitization is
persistent into adulthood in the PCP-induced hyperlocomotion test, and then examined the
potential involvement of asenapine-induced change in ΔFosB protein in the sensitization.
We decided to examine this protein instead of D2 and BDNF because results from
Experiment 1 did not reveal any significant group differences in the expression of D2 and
BDNF in spite of the conspicuous asenapine sensitization effect. ΔFosB is a transcription
factor that plays an important role in long-term neuroplasticity. Chronic administration of
antipsychotic drugs causes ΔFosB induction in the striatum and frontal cortex [29, 31, 37].
Shu et al. Page 6













The experiment was comprised of three phases: Repeated asenapine testing during
adolescence, asenapine challenge test during adulthood and ΔFosB Western blotting. Table
2 details the experimental procedure.
Five days of repeated asenapine testing from P41 to P 45—Forty-eight adolescent
rats (∼P 41) were randomly assigned to 1 of 5 groups: VEH+VEH (saline+saline, n = 16),
VEH+PCP (saline+PCP 2.00 mg/kg, n = 8); ASE 0.05+PCP (ASE 0.05 mg/kg+PCP 2.00
mg/kg, n = 8), ASE 0.10+PCP (ASE 0.10 mg/kg+PCP 2.00 mg/kg, n = 8), and ASE
0.20+PCP (ASE 0.20 mg/kg+PCP 2.00 mg/kg, n = 8). They were first handled and
habituated to the locomotor activity apparatus for 2 days (30 min/day). On each of the next 5
days, they were first injected with saline, asenapine 0.05, 0.10, or 0.20 mg/kg and then
immediately placed in the boxes for 30 min. At the end of the 30-min period, they were
taken out and injected with saline or PCP (2.00 mg/kg, sc) and placed back in the boxes for
another 60 min. Locomotor activity (number of photobeam breaks) was measured in 5 min
intervals throughout the entire 90-min testing session.
Asenapine challenge test during adulthood on ∼P 76—Twenty-eight days after the
last (5th) asenapine test, after the rats became adults (∼P 75), all rats were returned to the
locomotor activity boxes for 1 re-habituation session (30 min), followed by the asenapine
challenge test 1 day later (∼P 76). On the challenge day, the VEH+VEH group was split
into two subgroups (n = 8/subgroup): the VEH+VEH-1 group and VEH+VEH-2 group. All
rats were first injected with asenapine 0.10 mg/kg and then immediately placed in the
locomotor activity boxes for 30 minutes. At the end of the 30-min period, they were taken
out and injected with either saline (VEH+VEH-1, n = 8) or PCP (2.00 mg/kg) (VEH+VEH-2
and rats in other groups) and placed back in the boxes for another 60 min. Locomotor
activity was recorded for the entire 90-min testing session. Due to a mechanical error, data
from 1 rat in the asenapine 0.05+PCP group were lost on the 5th day of asenapine testing,
and were excluded from data analysis.
Western blot analysis—As described above, 1 day after the challenge test (∼P 76), rats
were sacrificed by live decapitation and their brain samples were used for Western blotting
of ΔFosB (1:200, Cell Signaling Technology, Danvers, MA) following the protocol
described in Experiment 1.
2.7. Statistical Analysis
All data were expressed as mean + SEM. Data from the 5 drug test sessions (e.g. avoidance
response and PCP-induced hyperlocomotion) were analyzed using a factorial repeated
measures analysis of variance (ANOVA) with the between-subjects factor being drug groups
and the within-subjects factor being test days, followed by post hoc LSD tests. Differences
between groups on the specific drug test days and on the challenge tests were analyzed using
one-way ANOVAs, followed by post hoc LSD tests (for more than 3 groups). For all
analyses, p ≤ 0.05 was considered statistically significant and all data were analyzed using
SPSS version 21.
Shu et al. Page 7













The BDNF, D2 and ΔFosB proteins were quantified by normalizing to β-actin, and was
either re-probed or co-probed on the same membrane and then calculated as percentage of
the corresponding control group (deemed to be 100%). Group and regional differences on
the BDNF and D2 expressions were analyzed using repeated measures ANOVA [4 (group) ×
3 (region)]. While the ΔFosB expression was analyzed using repeated measures ANOVA [6
(group) × 3 (region)].
3. Results
3.1. Experiment 1: Asenapine sensitization and associated D2 and BDNF protein
expression in asenapine-treated rats in the conditioned avoidance response test
Repeated asenapine treatment suppressed avoidance response in adolescent
rats—Figure 1A shows the mean number of avoidance responses on the last training (pre-
drug) day and 5 drug test days. There was no group difference on the last training day (pre-
drug). Throughout the 5 drug test days, asenapine increased its suppression of avoidance
response progressively and dose-dependently. Two-way repeated measures ANOVA
revealed a main effect of group, F(3, 36) = 20.433, p < 0.001; day, F(4, 144) = 26.335, p <
0.001 and a significant group × day interaction, F(12, 144) = 2.051, p = 0.024. Post hoc LSD
tests showed that all 3 asenapine groups made significantly fewer avoidance responses than
the saline group, all p ≤ 0.001, and both ASE 0.10 and ASE 0.20 groups also made
significantly fewer avoidance responses than the ASE 0.05 group, p = 0.032 and p = 0.001,
respectively. The group × day interaction was due to the faster decline of avoidance
responding in the 3 asenapine groups across the test days and a relatively stable high level of
avoidance in the saline group.
Figure 1B shows the mean number of 22 kHz USV counts recorded for the first 10 min on
the last training (pre-drug) day and 5 drug test days. There were more 22 kHz USVs on the
pre-drug day (with shock) than on the drug test days (no shock). Repeated measures
ANOVA revealed a main effect of day, F(4, 144) = 2.735, p = 0.031, but no significant main
effect of group, F(3, 36) = 0.789, p = 0.508 and no significant group × day interaction, F(12,
144) = 0.973, p = 0.478, possibly due to the floor effect.
Adolescent asenapine exposure potentiated behavioral reactivity to
asenapine re-exposure in adulthood—Figure 2A shows the number of avoidance
responses on the 7th retraining day (pre-drug day) and the asenapine challenge test day (∼P
76). No significant group difference was found on the pre-drug day. On the challenge day
when all rats were injected with ASE 0.10 mg/kg, there was a main effect of group, F(3, 36)
= 8.294, p < 0.001. All 3 asenapine groups made fewer avoidance responses than the saline
group. Post hoc LSD tests showed that the ASE 0.10 and ASE 0.20 groups had significantly
lower avoidance than the VEH group, p = 0.003 and p < 0.001, respectively. The ASE 0.10
group and the ASE 0.20 group also had significantly lower avoidance than the ASE 0.05
group, p = 0.018 and p = 0.001, respectively. In contrast, the group differences on the 22
kHz USVs on the pre-drug day and on the challenge test day were not significant (Figure
2B), p > 0.584.
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Levels of BDNF and D2 receptor expression were not different among the
groups—As shown in Figure 3, the group difference of the BDNF protein levels among the
4 groups did not appear to be significant. Two-way repeated measures ANOVA with the
group as the between-subjects factor and brain site (e. g. PFC, hippocampus and striatum) as
the within-subjects factors did not find a main effect of group, F(3, 20) = 0.635, p = 0.601 or
significant interaction between the two, F(6, 40) = 0.644, p = 0.694. However, there was a
significant main effect of brain site, F(2, 40) = 4.847, p = 0.013, with a relatively higher
level of BDNF expression found in the striatum. Similarly, on the D2 receptor expression
(Figure 4), the main effect of group, F(3, 28) = 0.149, p = 0.929 and group × brain site
interaction, F(6, 56) = 0.766, p = 0.600, were not significant, while the main effect of brain
site was, F(2, 56) = 3.486, p = 0.037. Again, the striatum appears to have a higher level of
D2 receptors than other brain regions.
3.2. Experiment 2: Asenapine sensitization and associated ΔFosB protein expression in
asenapine-treated rats in the PCP-induced hyperlocomotion test
Repeated asenapine treatment suppressed spontaneous and PCP-induced
motor activity in adolescent rats—Figure 5A shows the mean motor activity of the 5
groups of rats during the 30-min period before PCP or saline injection throughout the 5 days
of drug testing (a measure of spontaneous motor activity). Two-way repeated measures
ANOVA revealed a main effect of group, F(4, 43) = 7.460, p < 0.001; and a main effect of
test day, F(4, 172) = 36.285, p < 0.001; but no significant group × day interaction, F(16,
172) = 1.478, p = 0.113. Post hoc LSD analyses revealed that the 3 asenapine groups had
significantly lower motor activity than the VEH+VEH group, all p < 0.001. The ASE
0.10+PCP group and the ASE 0.20+PCP group also had significantly lower motor activity
than the VEH+PCP group, p = 0.045 and p = 0.010, respectively, confirming the strong
inhibitory effect of asenapine on spontaneous motor activity. The main effect of day was
attributed to a sharp decline in motor activity from day 1 to day 2 across all groups.
Figure 5B shows the mean motor activity of 5 groups during the 60-min test period after
saline or PCP injection throughout the 5 days of drug testing. Two-way repeated measures
ANOVA revealed a main effect of group, F(4, 42) = 30.489, p < 0.001; and a significant
group × day interaction, F(16, 168) = 2.447, p = 0.002; but no main effect of day, F(4, 168)
= 2.057, p = 0.089. Post hoc LSD tests revealed that the VEH+PCP group had significantly
higher motor activity than the VEH+VEH group, p < 0.001, confirming the strong
psychomotor activating effect of this dose of PCP. The medium ASE (0.10 mg/kg) dose
group and the high ASE (0.20 mg/kg) dose group had significantly lower motor activity than
the VEH+PCP group, p = 0.042 and p < 0.001, respectively. In addition, all 3 asenapine
groups differed significantly from each other, all p ≤ 0.004. The significant group × day
interaction was mainly due to the progressive increase in motor activity in the ASE 0.05
group and a concurrent decline in the ASE 0.10 and 0.20 groups throughout the test days.
Re-habituation session in adulthood on ∼P 75—On ∼P 75 before the asenapine
challenge test, all rats were placed in the motor activity boxes for 30 min with no drug
treatment, and one-way ANOVA did not find any significant group difference, F(5, 41) =
1.355, p = 0.261 (Figure 6A).
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Adolescent asenapine treatment enhanced its inhibition of spontaneous
motor activity in the asenapine challenge test on ∼P 76—Figure 6B shows the
mean motor activity during the 30-min test period before the PCP or saline injection on the
asenapine challenge test day (∼P 76). One-way ANOVA confirmed a main effect of group,
F(5,41) = 6.192, p < 0.001. Post hoc LSD tests showed that the ASE 0.10 and ASE 0.20
groups were significantly different from the VEH+VEH-1 group and VEH+VEH-2 group,
allp < 0.004; and different from the VEH+PCP group, p = 0.033 and p = 0.004, respectively,
indicating a potentiated inhibition of spontaneous motor activity due to adolescent asenapine
treatment. The ASE 0.20 group are also different from the ASE 0.05+PCP group, p = 0.011.
Figure 6C shows the mean motor activity during the 60-min test period after the saline or
PCP injection on the asenapine challenge test day. Independent samples t test found that the
VEH+VEH-2 group (treated with PCP) had significantly higher motor activity than the VEH
+VEH-1 group (treated with saline), t(14) = −5.516, p = 0.001, confirming the psychomotor
stimulating effect of PCP. One way ANOVA on the PCP-treated groups (5 groups excluding
the VEH+VEH-1 group) found no significant main effect of group, F(4.34) = 1.860, p =
0.140.
ΔFosB expression did not differ between groups—As shown in Figure 7, the group
and regional differences of the ΔFosB expression did not appear to be significant. Two-way
repeated measures ANOVA with the group as the between-subjects factor and brain site
(e.g. PFC, striatum and hippocampus) as the within-subjects factors did not find a main
effect of group, F(5, 42) = 0.187, p = 0.332, or the significant group × brain site interaction,
F(10, 84) = 1.035, p = 0.422. However, there was a significant main effect of brain site, F(2,
84) = 62341, p < 0.001, with a relatively higher level of ΔFosB expression found in the PFC
than in other brain areas.
4. Discussion
Our results show that repeated asenapine treatment in adolescence for only 5 days induced a
long-term sensitized inhibition of avoidance responding and spontaneous motor activity that
persisted into adulthood. These results are similar to what we previously reported on
olanzapine and risperidone [13-16]. The only exception is that this sensitization effect in the
PCP test was manifested mainly in the measurement of spontaneous motor activity and less
in that of PCP-induced hyperlocomotion. In contrast to our expectation, we did not find any
significant group differences on the protein levels of BDNF, D2 and ΔFosB in adult rats that
were treated with asenapine or vehicle in adolescence. Therefore, although repeated
adolescent asenapine administration induced a strong across-developmental sensitization
effect in two validated behavioral tests of antipsychotic activity, this effect did not appear to
be mediated by BDNF, D2 and ΔFosB.
Previous work on the avoidance-disruptive effect of asenapine has focused on its acute
effect [33]. We recently showed that with repeated asenapine administration, its avoidance-
disruptive effect intensified across test sessions in adult rats [18, 19]. For example,
asenapine at 0.05 mg/kg did not show a significant disruptive effect on avoidance until the
3rd test day. The present study found a similar effect in adolescent rats with the significant
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disruption occurred from the 2nd day on. These findings clearly demonstrated that repeated
asenapine exposure altered drug sensitivity and this alteration may be stronger in adolescent
rats than adult rats. Although the long-lasting nature of asenapine sensitization has been
demonstrated before by us in adult rats, showing that asenapine sensitization could last up to
50 days since the last drug treatment [19], the present finding that it could be maintained
throughout the adolescent development period into adulthood further solidified this feature,
as it suggests that this drug memory effect is resistant to potential alterations due to brain
maturation. Because this property of asenapine sensitization is no different from those of
olanzapine and risperidone, it may be a general property of antipsychotic drugs except
clozapine (clozapine causes a tolerance).
In the present study, we also examined the asenapine sensitization effect in the PCP-induced
hyperlocomotion test in adolescent rats, which, to our knowledge, has not been explored
before. However, the significant sensitization effect was only found in the asenapine
challenge test in the first 30-min test period after ASE 0.10 mg/kg injection, a period that
measures the inhibition of asenapine on spontaneous motor activity. No significant
sensitization effect was detected in the 60-min test period after PCP challenge. This lack of
sensitization in the PCP-induced hyperlocomotion is in contrast to our adolescent olanzapine
study, in which we found the sensitization effect in both the spontaneous motor activity and
PCP-induced hyperlocomotion [16]. It is also different from our recent adult rat study in
which we demonstrated a dose-dependent asenapine sensitization in the PCP-induced
hyperlocomotion [18]. The exact causes of these discrepancies are not clear, but may be due
to differences in drug property (asenapine vs. olanzapine) or other experimental factors (e.g.
32 days vs. 3 days interval between repeated testing and challenge or PCP drug dose 2.00 vs.
3.20 mg/kg). Given that all antipsychotic drugs suppress both spontaneous motor activity
and PCP-induced hyperlocomotion, and both effects putatively reflect their antipsychotic
activity [38], it is safe to conclude that adolescent asenapine treatment causes a long-lasting
increase in drug sensitivity in adult rats previously exposed to asenapine in adolescence.
This conclusion is also consistent with our finding from the CAR test.
In our previous adolescent olanzapine, risperidone and clozapine studies, we noted that there
was a rebound of spontaneous motor activity on the re-habituation days when all rats were
tested drug-free and presumably in a drug withdrawal state [16, 39]. Rats treated with these
drugs were more active in the 30-min period in the test boxes than those previously treated
with vehicle. In the present study, we did not observe any rebound effect associated with
adolescent asenapine treatment. The exact reason is not clear, as asenapine shares similar
affinity and potency for blocking dopamine, serotonin, α-adrenergic and histamine receptors
[25, 40]. It could be due to the unique combination of its action on these receptors, such as
its preferential actions on 5-HT2A, 5-HT2C, 5-HT2B, 5-HT1A, 5-HT1B, 5-HT6 and 5-HT7; D2
and D3, α2A, α2B, α2C and H1. As suggested before, this rebound effect resembles to some
extent the antipsychotic withdrawal-induced behavioral hypersensitivity, possibly reflecting
drug-induced increase in dopamine neurotransmission via D2 (especially D2high) receptors
[41-45], the lack of this effect suggests that adolescent asenapine treatment may not alter D2
receptor levels, a finding consistent with our Western blotting data.
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Our previous work demonstrated that asenapine at 0.05 mg/kg actually increased PCP-
induced hyperlocomotion, an effect opposite to those of 0.10 and 0.20 mg/kg asenapine in
adult rats [18]. This same effect was noted in adolescent rats (Figure 5B and 6C). This
enhanced effect on PCP-induced hyperlcomotion may be related to its putative procognitive
effect at low doses or its potential antidepressant effect. This notion is based on reports that
asenapine at low doses are shown to improve certain cognitive deficits (e.g. reversal
learning, cognitive flexibility, object recognition, etc.) induced by PCP or brain lesions
[46-48]; and several commonly used antidepressants also increase the PCP-induced
hyperlocomotion [49]. Future research should address the clinical relevance of this
behavioral effect of asenapine.
In searching for the molecular basis of asenapine sensitization, we focused our attention on
D2, BDNF and ΔFosB for the following reasons. First, all antipsychotic drugs antagonize
dopamine D2 receptors [50] and repeated treatment with certain antipsychotics is shown to
increase D2 expression in the hippocampus and striatum in both adolescent and adult rats
[4]. Second, previous work from our lab has shown that risperidone-induced sensitization in
the CAR test is related to drug-induced increase in D2 sensitivity as assessed in the
quinipirole (a D2/3 agonist)-induced hyperlocomotion test [19]. Pretreatment of quinpirole is
also shown to attenuate olanzapine sensitization in the CAR test in adult rats [23]. Third,
BDNF is known for its role in brain development and drug-induced neuroplasticity [51-53].
Antipsychotic drugs, especially upon repeated chronic administration, can also alter the
brain levels of BDNF [27, 54, 55] (but see [56]) and prevent the stress-induced decrease in
the levels of BDNF [27, 54, 56-59]. One recent study suggests that adolescent treatment of
lurasidone prevented the reduction of prefrontal BDNF expression in adult rats that were
exposed to prenatal stress [60]. Fourth, it is well established that repeated antipsychotic
treatment causes an increase in ΔFosB in several forebrain areas (e.g. striatum and prefrontal
cortex) and this effect may be dependent on antagonism of D2 dopamine receptors [29].
Based on these findings, it is reasonable to expect that repeated asenapine treatment in
adolescence would induce long-lasting changes in D2, BDNF and ΔFosB levels in the brain
regions implicated in the clinical actions of antipsychotic drugs. However, we did not find
any significant group differences in all 3 proteins in adult rats that were exposed to
asenapine and those to saline during adolescence. At least three reasons may explain for
these negative findings. First, the asenapine treatment might have been too short to induce
significant changes. It is possible that 5 days of asenapine was not enough to induce long-
lasting changes in D2, BDNF and ΔFosB that could be detected in adulthood. In fact, much
of previous antipsychotic work on these molecules utilized longer treatment regimens (>21
days) [4, 5]. The second reason is that asenapine challenge could potentially alter D2, BDNF
and ΔFosB expression acutely, thus masking the prior adolescent asenapine treatment-
induced changes in these proteins. Third, the doses tested might not be optimal to induce
robust changes that last throughout the development and the method (Western blotting) may
not be sensitive enough. The lack of strong group differences on these proteins seems to
suggest that asenapine sensitization from adolescence to adulthood is not likely mediated by
the persistent and region-specific changes in D2, BDNF and ΔFosB. Our finding on BDNF
is also consistent with our recent study showing that repeated risperidone treatment in
adolescence did not alter BDNF protein levels in the prefrontal cortex, hippocampus and
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striatum in the PCP-induced hyperlocomotion test [39]. This conclusion may be premature
as more studies are clearly needed to verify our findings.
If D2, BDNF and ΔFosB are not involved in the mediation of asenapine sensitization, what
molecular action of asenapine could explain its long-lasting effect? At this point, we could
only speculate. Because asenapine has relatively higher affinities for 5-HT2C, 5-HT2A, 5-
HT2B, 5-HT7, 5-HT6, α2B, and D3 receptors relative to D2 receptor, it is possible that these
targets are involved in mediating the clinical actions of asenapine, and possibly its
sensitization effect. This possibility is enhanced by the findings that chronic asenapine
treatment decreases 5-HT2A receptor binding [61, 62] and dose-dependently increases
extracellular dopamine release in the medial prefrontal cortex [33, 63]. Future research
needs to examine the asenapine-induced changes in these proteins and identify their roles in
asenapine sensitization.
Adolescence (human: 10-19 years old; rats: 35-60 days old) is a period in which the brain
and various psychological functions undergo dramatic transitions [64]. It is also the time
when symptoms of a variety of severe mental disorders often manifest. Extensive studies
have shown that exposure to drugs of abuse during this period increases vulnerability to
drug addiction in adulthood and is detrimental to many psychological functions in the long
run [65]. The present study, together with several others, reveal that exposure to
psychotherapeutic drugs could also alter drug sensitivity and change psychological
functions. Some effects are desirable [9-12], while others are not [5, 8]. One important
contribution of preclinical antipsychotic research is its ability to comprehensively reveal
various behavioral and brain effects due to adolescent antipsychotic treatment. Such
knowledge can then be translated into clinical practice to help guide drug dosing for patients
with or without prior drug experience.
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1. Five days of asenapine treatment in adolescence caused a sensitization in
adulthood;
2. Asenapine sensitization was demonstrated in a conditioned avoidance response
test;
3. Asenapine sensitization was demonstrated in a phencyclidine-induced
hyperlocomotion test;
4. Adolescent asenapine treatment did not cause a long-term change in the levels
of BDNF, D2 receptor and ΔFosB.
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Repeated asenapine treatment increased the suppression of avoidance response but did not
affect 22 kHz USV at adolescence. Number of avoidance responses (A) and 22 kHz USV
count (B) made by the rats from the ASE (0.05 mg/kg), ASE (0.10 mg/kg), ASE (0.20
mg/kg) and vehicle groups on the last training (pre-drug) day and throughout the 5 drug test
days are expressed as mean + SEM. **p < 0.001, three asenapine groups relative to the VEH
group; #p < 0.05, ASE 0.10 and ASE 0.20 groups relative to the ASE 0.05 group
respectively.
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Prior asenapine treatment increased sensitivity to asenapine re-exposure in the challenge test
in adulthood. Number of avoidance responses (A) and 22 kHz USV counts (B) on the 7th re-
training (pre-drug) day and the ASE 0.10 mg/kg challenge test day, are expressed as mean +
SEM. **p < 0.004 relative to VEH group; #p < 0.05, ##p = 0.001 relative to ASE 0.05
group, respectively.
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BDNF protein levels and representative blots in the prefrontal cortex (PFC) (A), striatum
(B) and hippocampus (C) in the 4 groups of rats previously treated with vehicle and ASE
0.05, 0.10 or 0.20 mg/kg for 5 days and challenged with ASE 0.10 mg/kg on PND 76. Group
data (Mean + SEM, n = 6-8) are expressed as the ratio of mean values in the VEH group.
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D2 receptor protein levels and representative blots in the prefrontal cortex (PFC) (A),
striatum (B) and hippocampus (C) in the 4 groups of rats previously treated with vehicle or
ASE 0.05, 0.10 or 0.20 mg/kg for 5 days and challenged with ASE 0.10 mg/kg on ∼P 76.
Group data (Mean + SEM, n = 8) are expressed as the ratio of mean values in the VEH
group.
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Asenapine treatment suppressed PCP-induced hyperlocomotion throughout the 5 test days in
adolescence. Locomotor activity was measured for 30 min before PCP (2.00 mg/kg) or
vehicle injection (A) and for 60 min after PCP (2.00 mg/kg) or vehicle injection (B) are
expressed as mean + SEM for each group (VEH: n = 16; others: n = 8/group). ASE (0.05,
0.10 and 0.20 mg/kg) was injected 30 min before the vehicle or PCP (2.00 mg/kg) injection.
**p < 0.001 relative to VEH+VEH group; #p < 0.05, ##p < 0.010 relative to VEH+PCP
group; &&p < 0.003 relative to ASE 0.05+PCP group; $p = 0.003 relative to ASE 0.10+PCP
group.
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Adolescent asenapine treatment increased the inhibition of spontaneous motor activity
asenapine re-exposure in adulthood. Locomotor activity was measured for 30 min on the re-
habituation day (∼P 75) and is expressed as mean + SEM (A). Locomotor activity was
measured for 30 min before PCP (2.00 mg/kg) or vehicle injection (B) and for 60 min after
PCP (2.00 mg/kg) or vehicle injection (C). ASE 0.10 mg/kg was injected 30 min before the
PCP (2.00 mg/kg) or vehicle injection. **p ≤ 0.001 relative to VEH+VEH-1 group; ##p <
0.004 relative to VEH+VEH-2 group; &p < 0.05, &&p < 0.005 relative to VEH+PCP group;
$p = 0.011, relative to ASE 0.05+PCP group.
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ΔFosB protein levels and representative blots in the prefrontal cortex (PFC) (A), striatum
(B) and hippocampus (C) in the 6 groups of rats previously treated with vehicle, ASE 0.05,
0.10 or 0.20 mg/kg and PCP 2.00 mg/kg for 5 days and challenged with vehicle+vehicle
(VEH+VEH-1 group) or ASE 0.10 mg/kg followed by PCP 2.00 mg/kg on ∼P 76. Group
data (Mean + SEM, n = 8) are expressed as the ratio of mean values in the VEH+VEH-1
group.
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Table 1
Timeline of events in Experiment 1 (CAR model)
Days of study Approximate age (days) Manipulation
1-2 PND 31-32 Habituation to CAR boxes (30 min/day)
3-12 PND 33-42 10 Days of CAR training (CS–US)
13–17 PND 43-47 5 Days of drug testing (CS-only)
18-37 PND 48-67 Rest
38 PND 68 Habituation to CAR boxes (30 min/day)
39-45 PND 69-75 7 days of CAR retraining (CS–US)
46 PND 76 Challenge test (CS-only): ASE 0.10 mg/kg
47 PND 77 Collection of brain samples
ASE: asenapine; VEH: vehicle; PND: postnatal day.
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Table 2
Timeline of events in Experiment 2 (PCP model)
Days of study Approximate age (years) Manipulation
1-2 PND 41-42 Habituation to Locomotor boxes (30 min/day)
3-7 PND 43-47 5 Days of drug testing (30+60 min): VEH/ASE (0.05, 0.10, 0.20 mg/kg) + VEH or PCP 2.00
mg/kg
8-34 PND 48-74 Rest
35 PND 75 Habituation to Locomotor boxes (30 min/day)
36 PND 76 Challenge test (30+60 min): ASE 0.10 mg/kg + VEH or PCP 2.00mg/kg
37 PND 77 Collection of brain samples
ASE: asenapine; PCP: phencyclidine; VEH: vehicle; PND: postnatal day.
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